| |
| Emerging requirements for infectious disease IVD quality control material |  |
| |
| Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Controls |  |
| Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods |  |
| Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel |  |
| |
| Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control |  |
| Performance of NAAT that detect MGEN using Swab Quality Controls |  |
| Evaluating the Performance of Emerging STI Point of Care Assays Using Novel, Room Temperature Stable CT/NG/TV/MG Positive Swab Quality Control Materials |  |
| |
| Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing |  |
| Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples |  |
| Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control |  |
| Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls |  |
| Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control |  |
| Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control |  |